Phenylketonuria (PKU): A problem solved?

详细信息    查看全文

• 作者：Christine S. Brown^a ; ^{Christine.brown@npkua.org" class="auth_mail" title="E-mail the corresponding author} ; Uta Lichter-Konecki^b ; ^{Uta.Lichter-Konecki@DrexelMed.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ACMG ; American College of Medical Genetics and Genomics ; NPKUA ; National PKU Alliance ; PAH ; phenylalanine hydroxylase ; Phe ; phenylalanine ; PKU ; phenylketonuria
• 刊名：Molecular Genetics and Metabolism Reports
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：6
• 期：Complete
• 页码：8-12
• 全文大小：330 K

文摘

Phenylketonuria (PKU) is a rare metabolic disorder characterized by impaired conversion of phenylalanine (Phe) to tyrosine. If left untreated, the resultant accumulation of excess blood Phe can cause physiological, neurological, and intellectual disabilities. The National PKU Alliance (NPKUA) conducted a survey of its membership to assess current health status and interest in new treatments for PKU. Of the 625 survey respondents, less than half (46.7%) reported blood Phe within (120–360 μmol/L) — the range recommended by the American College of Medical Genetics and Genomics (ACMG). The survey results also showed that younger (≤ 18 years) individuals were about 3-times as successful in keeping their blood Phe concentrations within the recommended clinical range compared with adults. Blood Phe over 360 μmol/L was reported in one-quarter (25.5%) of ≤ 18 year old individuals and almost two-thirds (61.5%) of adults. A little more than half (51.7%) of respondents reported having difficulty in managing their PKU, including the maintenance of a Phe-restricted diet. Individuals with PKU desire new treatments that would allow them to increase their intake of natural protein, discontinue or reduce their intake of medical foods (medical formula and foods modified to be low in protein), improve their mental health (including a reduction in depression and anxiety), and a reduction of their blood Phe concentrations. Respondents preferred oral administration of any newly developed therapies and, in general, disliked therapeutic injections. Injections at home were preferred over injections at a clinic. Payers, government agencies, clinicians, and industry partners should consider patient input when developing and approving new therapies and treatments for PKU.